Precision Biosciences Stock Price To Earnings To Growth
| DTIL Stock | USD 4.84 0.22 4.76% |
Fundamental analysis of Precision BioSciences allows traders to better anticipate movements in Precision BioSciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Precision | Build AI portfolio with Precision Stock |
Precision BioSciences Company Price To Earnings To Growth Analysis
Precision BioSciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Precision BioSciences has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Precision Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Precision BioSciences' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Precision BioSciences could also be used in its relative valuation, which is a method of valuing Precision BioSciences by comparing valuation metrics of similar companies.Precision BioSciences is currently under evaluation in price to earnings to growth category among its peers.
Precision Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | (762.48) % | ||||
| Current Valuation | 6.19 M | ||||
| Shares Outstanding | 11.09 M | ||||
| Shares Owned By Insiders | 10.93 % | ||||
| Shares Owned By Institutions | 42.34 % | ||||
| Number Of Shares Shorted | 1.08 M | ||||
| Price To Earning | (6.10) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 1.05 X | ||||
| Revenue | 68.7 M | ||||
| Gross Profit | 51.14 M | ||||
| EBITDA | 13.53 M | ||||
| Net Income | 7.17 M | ||||
| Cash And Equivalents | 184.14 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 30.05 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 4.59 X | ||||
| Book Value Per Share | 4.68 X | ||||
| Cash Flow From Operations | (58.45 M) | ||||
| Short Ratio | 1.93 X | ||||
| Earnings Per Share | (3.02) X | ||||
| Target Price | 30.5 | ||||
| Number Of Employees | 107 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 53.67 M | ||||
| Total Asset | 136.39 M | ||||
| Retained Earnings | (482.46 M) | ||||
| Working Capital | 80.01 M | ||||
| Current Asset | 174.05 M | ||||
| Current Liabilities | 23.86 M | ||||
| Net Asset | 136.39 M |
About Precision BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Precision BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Precision BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Precision BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Precision BioSciences Piotroski F Score and Precision BioSciences Altman Z Score analysis. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.